Preventive Effect of Phosphodiesterase Inhibitor Pentoxifylline Against Medication-Related Osteonecrosis of the Jaw: An Animal Study

被引:13
|
作者
Yalcin-Ulker, Gul Merve [1 ]
Cumbul, Alev [2 ]
Duygu-Capar, Gonca [3 ]
Uslu, Unal [2 ]
Sencift, Kemal
机构
[1] Okan Univ, Dept Oral & Maxillofacial Surg, Fac Dent, 23-A Mecidiyekoy, Istanbul, Turkey
[2] Yeditepe Univ, Dept Histol & Embryol, Fac Med, Istanbul, Turkey
[3] Trakya Univ, Dept Oral & Maxillofacial Surg, Fac Dent, Edirne, Turkey
关键词
BISPHOSPHONATE-RELATED OSTEONECROSIS; SURGEONS POSITION PAPER; ZOLEDRONIC ACID; TNF-ALPHA; CANCER-PATIENTS; AMERICAN ASSOCIATION; ORAL BISPHOSPHONATES; DENTAL EXTRACTIONS; RISK-FACTORS; IN-VITRO;
D O I
10.1016/j.joms.2017.04.017
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Purpose: The aim of this experimental study was to investigate the prophylactic effect of pentoxifylline (PTX) on medication-related osteonecrosis of the jaw (MRONJ). Materials and Methods: Female Sprague-Dawley rats (n=33) received zoledronic acid (ZA) for 8 weeks to create an osteonecrosis model. The left mandibular second molars were extracted and the recovery period lasted 8 weeks before sacrifice. PTX was intraperitoneally administered to prevent MRONJ. The specimens were histopathologically and histomorphometrically evaluated. Results: Histomorphometrically, between the control and ZA groups, there was no statistically significant difference in total bone volume (P=.999), but there was a statistically significant difference in bone ratio in the extraction sockets (P<.001). A comparison of the bone ratio of the ZA group with the ZA/PTX group (PTX administered after extraction) showed no statistically significant difference (P=.69), but there was a statistically significant difference with the ZA/PTX/PTX group (PTX administered before and after extraction; P=.008). Histopathologically, between the control and ZA groups, there were statistically significant differences for inflammation (P=.013), vascularization (P=.022), hemorrhage (P=.025), and regeneration (P=.008). Between the ZA and ZA/PTX groups, there were no statistically significant differences for inflammation (P=.536), vascularization (P=.642), hemorrhage (P=.765), and regeneration (P=.127). Between the ZA and ZA/PTX/PTX groups, there were statistically significant differences for inflammation (P=.017), vascularization (P=.04), hemorrhage (P=.044), and regeneration (P=.04). Conclusion: In this experimental model of MRONJ, it might be concluded that although PTX, given after tooth extraction, improves new bone formation that positively affects bone healing, it is not prophylactic. However, PTX given before tooth extraction is prophylactic. Therefore, PTX might affect healing in a positive way by optimizing the inflammatory response. (C) 2017 American Association of Oral and Maxillofacial Surgeons
引用
收藏
页码:2354 / 2368
页数:15
相关论文
共 50 条
  • [41] Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw
    Metwally, Tarek
    Burke, Andrea
    Tsai, Jeffrey Y.
    Collins, Michael T.
    Boyce, Alison M.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2016, 74 (10) : 1983 - 1999
  • [42] Animal model for medication-related osteonecrosis of the jaw with precedent metabolic bone disease
    Kim, Jin-Woo
    Tatad, Jacquiline Czar I.
    Landayan, Maria Erika A.
    Kim, Sun-Jong
    Kim, Myung-Rae
    BONE, 2015, 81 : 442 - 448
  • [43] Vitamin D supplementation: Hypothetical effect on medication-related osteonecrosis of the jaw
    Lorenzo-Pouso, Alejandro I.
    Perez-Sayans, Mario
    Garcia, Abel
    Carballo, Javier
    MEDICAL HYPOTHESES, 2018, 116 : 79 - +
  • [44] Pathophysiology of Medication-Related Osteonecrosis of the Jaw-A Minireview
    Tetradis, Sotirios
    Allen, Matthew R.
    Ruggiero, Salvatore L.
    JBMR PLUS, 2023, 7 (08)
  • [45] Position paper on medication-related osteonecrosis of the jaw (MRONJ)
    Svejda B.
    Muschitz C.
    Gruber R.
    Brandtner C.
    Svejda C.
    Gasser R.W.
    Santler G.
    Dimai H.P.
    Wiener Medizinische Wochenschrift, 2016, 166 (1-2) : 68 - 74
  • [46] Diabetes as a Risk Factor for Medication-Related Osteonecrosis of the Jaw
    Peer, A.
    Khamaisi, M.
    JOURNAL OF DENTAL RESEARCH, 2015, 94 (02) : 252 - 260
  • [47] Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)
    Ristow, Oliver
    Otto, Sven
    Troeltzsch, Matthias
    Hohlweg-Majert, Bettina
    Pautke, Christoph
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2015, 43 (02) : 290 - 293
  • [48] Treatment of medication-related osteonecrosis of the jaw with cell therapy
    Bouland, Cyril Lucien
    Javadian, Rokneddine
    Gilis, Sarah
    Yanni, Antoine
    Le Clercq, Maxime
    Mestrallet, Pierre
    Kampouridis, Stelianos
    Bron, Dominique
    Lalmand, Martin
    Vanden Eynden, Xavier
    Boutremans, Edward
    Dequanter, Didier
    Loeb, Isabelle
    Philippart, Pierre
    Lagneaux, Laurence
    Meuleman, Nathalie
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [49] Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw
    He, Lina
    Sun, Xiangyu
    Liu, Zhijie
    Qiu, Yanfen
    Niu, Yumei
    INTERNATIONAL JOURNAL OF ORAL SCIENCE, 2020, 12 (01)
  • [50] A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw
    Sukegawa, Shintaro
    Kanno, Takahiro
    Kawai, Hotaka
    Nakamura, Satoko
    Shibata, Akane
    Sukegawa-Takahashi, Yuka
    Nagatsuka, Hitoshi
    Furuki, Yoshihiko
    JOURNAL OF HARD TISSUE BIOLOGY, 2016, 25 (04) : 447 - 454